Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma

NCT06779461 is registered in ClinicalTrials.gov with InnoBM Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06779461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06779461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
Lead sponsor
InnoBM Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 31, 2025
Completion date
December 31, 2027
Enrollment
228 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable